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Abstract
Objectives—In this study, we have investigated the effects of cannabidiol (CBD) on myocardial
dysfunction, inflammation, oxidative/nitrosative stress, cell death and interrelated signaling
pathways, using a mouse model of type I diabetic cardiomyopathy and primary human
cardiomyocytes exposed to high glucose.
Background—CBD, the most abundant nonpsychoactive constituent of Cannabis sativa
(marijuana) plant, exerts antiinflammatory effects in various disease models and alleviates pain
and spasticity associated with multiple sclerosis in humans.
Methods—Left ventricular function was measured by pressure-volume system. Oxidative stress,
cell death and fibrosis markers were evaluated by molecular biology/biochemical techniques,
electron spin resonance spectroscopy and flow cytometry.
Results—Diabetic cardiomyopathy was characterized by declined diastolic and systolic
myocardial performance associated with increased oxidative-nitrosative stress, NF-κB and MAPK
(JNK and p-38, p38α) activation, enhanced expression of adhesion molecules (ICAM-1,
VCAM-1), TNF-α, markers of fibrosis (TGF-β, CTGF, fibronectin, collagen-1, MMP-2 and
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MMP-9), enhanced cell death (caspase 3/7 and PARP activity, chromatin fragmentation and
TUNEL) and diminished Akt phosphorylation. Remarkably, CBD attenuated myocardial
dysfunction, cardiac fibrosis, oxidative/nitrosative stress, inflammation, cell death, and interrelated
signaling pathways. Furthermore, CBD also attenuated the high glucose-induced increased
reactive oxygen species generation, NF-κB activation and cell death in primary human
cardiomyocytes.
Conclusions—Collectively, these results coupled with the excellent safety and tolerability
profile of cannabidiol in humans, strongly suggest that it may have great therapeutic potential in
the treatment of diabetic complications, and perhaps other cardiovascular disorders, by attenuating
oxidative/nitrosative stress, inflammation, cell death and fibrosis.
Keywords
diabetic complications; cannabinoids; oxidative stress; inflammation
Introduction
Cardiovascular complications are the leading cause of morbidity and mortality in diabetic
patients. Diabetic cardiomyopathy characterized by myocardial left ventricular dysfunction
(both diastolic and later systolic one), independent of atherosclerosis and coronary artery
disease, has been well documented in both humans and animals (1-3). The mechanism of
diabetic cardiac dysfunction is complex and involves increased oxidative/nitrosative stress
(4-7), activation of various downstream transcription factors, pro-inflammatory and cell
death pathways such as NF-κB (8,9), poly(ADP-ribose) polymerase (PARP) (10), and
MAPKs (11,12), inactivation of pro-survival pathways such as Akt (13), eventually
culminating in cell death (14), changes in the composition of extracellular matrix with
enhanced cardiac fibrosis and increased inflammation (15).
Various components of Cannabis sativa (marijuana) plant, termed cannabinoids (e.g. the
most characterized active ingredient, the delta 9-tetrahydrocannabinol (THC)), exert potent
analgesic effects through the activation of classic CB1 receptors located in the central
nervous system and anti-inflammatory properties through the activation of CB2 cannabinoid
receptors on immune cells (16). However, the major limitation of the therapeutic utility of
THC is the development of centrally mediated CB1-depend psychoactive effects (16).
Furthermore, CB1 receptor activation in the cardiovascular system by endocannabinoids
may also contribute to the pathophysiology of multiple cardiovascular diseases including
heart failure and atherosclerosis (17). In contrast to THC, cannabidiol (CBD), the most
abundant cannabinoid of Cannabis sativa, which has been approved for the treatment of
inflammation, pain and spasticity associated with multiple sclerosis in humans since 2005 in
Canada (18), does not bind to these receptors (19), therefore it is devoid of psychoactive
properties and has no potential to cause adverse cardiac toxicity (20). Importantly, CBD is
well tolerated without side effects when chronically administered to humans (21,22). A
previous study has demonstrated cardiac protection by CBD in myocardial ischemic
reperfusion injury (23); therefore, we have investigated the potential protective effects of
CBD in diabetic hearts and in primary human cardiomyocytes exposed to high glucose. Our
findings underscore the potential of CBD for the prevention/treatment of diabetic
complications.
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All the animal protocols conformed to the National Institutes of Health (NIH) guidelines and
were approved by the Institutional Animal Care and use Committee of NIAAA/NIH.
Diabetes was induced in 8-12 weeks C57/BL6J mice weighing 23-25g (male, Jackson
Laboratories, Bar Harbor, ME) by intraperitoneal (I.P.) injection of streptozotocin (STZ,
Sigma, St. Louis, MO) at the dose of 50 mg/kg dissolved in 100 mM citrate buffer pH 4.5
for 5 consecutive days. After one week, blood glucose levels were measured using Ascensia
Coutour Glucometer (Bayer HealthCare, NY) by mandibular puncture blood sampling. Mice
which had blood sugar values >250 mg/dl were used for the study. In the first set of
experiments 1 week diabetic mice were treated with cannabidiol (CBD; 1, 10 or 20 mg/kg
I.P) or vehicle for 11 weeks (Suppl.Fig.1). In another set of experiments, 8 weeks diabetic
mice were treated with CBD or vehicle for 4 weeks (Suppl.Fig.2). CBD was isolated as
described earlier (24). The corresponding control groups were treated with either vehicle or
CBD alone for the same duration. All the animals were provided with food and water ad
libitum.
Hemodynamic measurements in mice
Left ventricular performance was measured in mice anesthetized with 2% isoflurane as
previously described (25) (26).
Determination of SOD activity, MDA, GSH, GSSG, 4-HNE, protein carbonyl content
SOD activities and reduced/oxidized glutathione (GSH, GSSG), malondialdehyde (MDA),
4-HNE, protein carbonyl levels in the myocardial tissues were determined as described in
the appendix.
Determination of myocardial ROS by electron paramagnetic resonance spectrometer
(EPR) is described in the appendix.
Reverse transcription and real time PCR
Preparation of samples and reverse transcription and real time PCR experiments from heart
tissues and the primers are described in the appendix and Suppl. Table1.
Determination of PARP, caspase 3/7 activities, chromatin fragmentation, TUNEL and 3-
nitrotyrosine (3-NT) content
PARP and caspase 3/7 activities, chromatin fragmentation, TUNEL, and 3-nitrotyrosine (3-
NT) content in the heart homogenates and/or human cardiomyocyte extracts are described in
the appendix.
Western immunoblot analysis
Sample preparations, Western immunoblot analysis and sources of antibodies are described
in the appendix.
Immunohistochemistry
The immunohistochemistry/staining from frozen or formalin-fixed myocardial tissues
(nitrotyrosine, TUNEL, Sirius red) is described in the appendix.
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Human cardiomyocytes (HCM) along with the culture medium were purchased from
ScienCell Research Laboratories (Carlsbad, CA) and were maintained and treated as
described in the appendix.
Simultaneous determination of cytosolic and mitochondrial ROS generation and apoptosis
by flow cytometry
Mitochondrial superoxide/ROS generation and cell death were determined as described (27)
and detailed in the appendix.
Statistical analysis
Results are expressed as mean±SEM. Statistical comparisons were made by one way
ANOVA followed by Newman-Keuls post-hoc analysis using GraphPad Prism 5 software
(San Diego, CA). When heterogeneity of variance was present, ANOVA was performed
after logarithmic transformation of the data. Probability values of P<0.05 were considered
significant.
Results
Blood glucose levels, pancreas insulin content and body weights
Diabetic animals exhibited increased blood glucose levels (Suppl. Figs.1A&2A) with the
decrease in the body weight (Suppl. Fig.1D). Diabetic animals also had increased
glycosylated hemoglobin (HbA1c) levels with concomitant decline in the pancreas insulin
content (Suppl. Fig. 1B/2B). CBD or vehicle treatment (1, 10 or 20 mg/kg I.P) for 11 or 4
weeks, did not significantly alter the body weight/blood glucose level/pancreas insulin
content neither in control nor in diabetic animals (Suppl. Figs.1& 2).
CBD treatment attenuates diabetes-induced hemodynamic alterations
12 weeks of established diabetes was associated with impaired diastolic and systolic left
ventricular function, which was largely attenuated by the treatment with CBD for 11 weeks
(starting 1 week after the establishment of diabetes)(Fig.1). CBD treatment also improved
the diabetes-induced myocardial dysfunction when it was given for 4 weeks in 8 weeks
diabetic mice (Suppl.Fig.3.).
CBD treatment attenuates diabetes-induced myocardial oxidative stress
There was increased accumulation of lipid peroxides (Fig.2A,B), protein carbonyls (Fig.2C),
ROS generation (Fig.2D), expression of mRNA of various ROS generating NADPH
oxidases (p22phox,p67phox, gp91phox; Fig.2E) with concordant decrease of GSH/GSSG
ratio (Fig.2F) and attenuated activity of the superoxide eliminating enzyme, the superoxide
dismutase (SOD) (Fig.2G) in hearts of diabetic mice. These changes were attenuated when
mice were treated with CBD for 11 weeks during the course of the diabetes (Fig.2A-G).
CBD treatment attenuates diabetes-induced myocardial NF-κB activation and inflammation
As shown in (Fig.3A) there was a marked IκB-α degradation in the cytosol of diabetic
hearts, with increased phosphorylation of IκB-α leading to release of active p65NF-κB,
which subsequently translocates to the nucleus to induce the inflammatory and apoptotic
gene expressions (Fig.3B). Gel shift assay also confirmed the NF-κB activation in diabetic
hearts (Fig.3C). CBD treatment of diabetic mice inhibited the IκB-α and subsequent p65NF-
κB nuclear translocation (Fig.3A-C). CBD treatment also inhibited the NF-κB-dependent
mRNA and/or protein expression of adhesion molecules ICAM-1 and VCAM-1 (Fig.3D,F)
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and pro-inflammatory cytokine TNF-α (Fig.3E,G) respectively in the diabetic myocardial
tissues.
CBD treatments attenuates diabetes-induced nitrosative/nitrative stress
There was significant increase in inducible nitric oxide synthase (iNOS) expression (Fig.4A)
and 3-nitrotyrosine (3-NT) accumulation (Fig.4B-E) in hearts of diabetic mice compared to
vehicle or CBD alone treated mice. CBD treatment attenuated the diabetes-induced iNOS
expression and 3-NT accumulation (marker of nitrosative/nitrative stress) (Fig.4B-E).
CBD treatment attenuates diabetes-induced mitogen activated protein kinases (MAPKs)
activation and apoptosis
There was marked increase in the p38MAPK (Fig.5A) and JNK (Fig.5B) activation in the
myocardial tissues of diabetic mice. In addition, there was marked activation p38αMAPK
(Fig.5C) and slightly diminished p38βMAPK (Fig.5C) in the diabetic myocardium. There
was also activation of MAPKAPK-2 in the diabetic heart (Fig.5D). CBD treatment for 11
weeks significantly mitigated p38MAPK/JNK/p38αMAPK/MAPKAPK-2 activation, while
it was not effective in restoring the p38βMAPK levels. In addition, Akt activation was also
significantly hampered in the diabetic myocardium, which was attenuated with CBD
treatment (Fig.5E). In diabetic myocardium there was marked increase in caspase 3
cleavage, caspase 3/7 activity (Fig.6A,B), chromatin fragmentation and PARP activity (Figs.
6C,D), and enhanced apoptosis (Fig.6E and Fig.7); all these changes in diabetes were
attenuated by CBD treatment.
CBD treatment attenuates diabetes-associated myocardial fibrosis
Real time RT-PCR analysis revealed significant increases in the pro-fibrotic gene
expressions (Fig.8A) and in collagen deposition (Fig.8B) in diabetic hearts, and these were
attenuated by CBD (Fig.8).
CBD post-treatment following the establishment of diabetic cardiomyopathy attenuates
diabetes-induced myocardial oxidative/nitrosative stress, cell death and fibrosis
Remarkably, CBD 20 (mg/kg) treatment also attenuated the diabetes-induced increased
myocardial nitrative stress, cell death (Suppl.Fig.4) and fibrosis (Suppl.Fig.5) when it was
given for 4 weeks in 8 weeks diabetic mice.
CBD treatment attenuates high glucose (HG)-induced cytosolic and mitochondrial ROS
generation and 3-NT formation in human cardiomyocytes (HCM)
HG treatment of HCM for 48 hrs markedly increased cytosolic (Suppl.Fig.6A) and
mitochondrial (Suppl.Fig.6B) ROS/superoxide generation compared to cells treated with
either D-glucose 5 mM, L-glucose 30 mM, or CBD (4μM) alone for the same duration. CBD
markedly attenuated the HG-induced increased ROS generation (Suppl. Fig.6A,B) and 3-NT
accumulation in HCM (Suppl. Fig.6C).
CBD mitigates HG-induced NF-κB activation and apoptosis in HCM
HG treatment induced NF-κB activation (Suppl.Fig.7A,B) and increased apoptosis and
PARP-dependent cell death in cardiomyocytes (Suppl.Fig.8A,B); the anti-apoptotic activity
of CBD was mediated, at least in part, via its ability to modulate Akt activity (Suppl. Fig.
8A).
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Accumulating evidence suggests that increased oxidative/nitrosative stress coupled with
activation of various downstream pro-inflammatory and cell death pathways play pivotal
role in the development of complex biochemical, mechanical and structural alterations
associated with diabetic cardiomyopathy (11,14,15) (3,4,6,12). However, in spite of the
accumulating knowledge obtained during the past decades, the treatment of diabetic
cardiomyopathy still remains poor and largely symptomatic (1,2).
Cannabidiol, a nonpsychoactive component of marijuana, has been shown to exert anti-
inflammatory and antioxidant effects both in vitro and in various preclinical models of
neurodegeneration and inflammatory disorders, independent from classical CB1 and CB2
receptors (20). Furthermore, CBD has recently been reported to lower the incidence of
diabetes in non-obese diabetic mice (28) and to preserve the blood-retinal barrier in
experimental diabetes (29).
In the present study, we have evaluated the effects of CBD treatment (for 11 weeks
administered after the destruction of pancreatic beta cells and development of frank type 1
diabetes, as well as in 8 weeks diabetic animals for 4 weeks) on myocardial dysfunction,
inflammation, oxidative/nitrosative stress, cell death and interrelated signaling pathways,
using a mouse model of type I diabetic cardiomyopathy or primary human cardiomyocytes
exposed to high glucose. Since significant cardiac dysfunction in this model starts to
develop from 4 weeks of established diabetes (4,10) with gradually increasing fibrosis
thereafter (12,15) (peaking around 8 weeks of established diabetes), in the first treatment
protocol (Suppl.Fig.1A.) we aimed to study if CBD treatment can prevent the development
of characteristic alterations of type I diabetic cardiomyopathy, in the second (Suppl.Fig.2A)
if it is able to reverse these changes once they already developed.
Consistently with previous reports, diabetic cardiomyopathy was characterized by declined
diastolic and systolic myocardial performance associated with enhanced myocardial
expression of NADPH oxidase isoforms p22phox, p67phox, gp91phox, attenuated antioxidant
defense (decreased glutathione content and SOD activity) coupled with increased
myocardial reactive oxygen species generation and lipid peroxidation (4,6,10,12,15). The
high glucose-induced ROS generation besides inducing lipid peroxidation may also initiate
activation of various stress signaling pathways (e.g. jun Nterminal kinase and p38 MAPK).
Our results are also in agreement with previous studies demonstrating enhanced activation
of p38 MAPK and its downstream effector (p38 MAPKAPK-2) in diabetic cardiomyopathy
models and demonstrating that pharmacological inhibition of p38 MAPK signaling
attenuates the expression of cardiac inflammatory markers, such as TNF-α, IL-1β, and IL-6,
and collagen content associated with diabetic cardiomyopathy (11,12). Likewise, with recent
evidence supporting an emerging role of p38α activation in diabetic cardiomyopathy (12), in
addition to its already established role in mediating cell death during myocardial ischemic-
reperfusion injury. The high glucose induced-ROS generation also impairs important pro-
survival signaling pathways such as Akt in diabetic hearts (13), activates pro-inflammatory
and cell death pathways such as NF-κB (8,9) and nuclear enzyme poly(ADP)-ribose
polymerase 1(10), which in turn regulate expression of important pro-inflammatory
cytokines, cell adhesion molecules and iNOS. The latter results in increased nitrosative/
nitrative stress, which is also implicated in cardiovascular complications of diabetes (5). A
recent study has also suggested that the NF-κB activation may induce increased oxidative
stress and contributes to mitochondrial and cardiac dysfunction in type II diabetes(9).
Importantly, the oxidative-nitrosative stress, stress signaling and inflammatory pathways in
diabetic cardiomyopathy are closely interrelated eventually promoting the development
myocardial fibrosis (3,9,11,15,30).
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CBD treatment (Suppl.Fig.1.) was able to attenuate the oxidative-nitrosative stress
(decreased the myocardial ROS generation and expression of p22phox, p67phox, gp91phox,
restored glutathione content and SOD activity, decreased 3-NT formation) and alterations of
the above mentioned pro-survival (Akt) and stress signaling (p38, p38α, JNK) pathways in
diabetic hearts. It also attenuated the NF-κB activation, expression of iNOS, TNFα, and
ICAM-1, cell death and fibrosis in diabetic myocardium, and improved the associated
characteristic functional alterations. Importantly, CBD treatment was able to attenuate/
reverse (though to a lesser extent) some of the above mentioned diabetes-induced
myocardial biochemical and functional changes following the establishment of diabetic
cardiomyopathy with fibrosis (Suppl.Figs.2-5). CBD also attenuated the high glucose-
induced increased reactive oxygen and nitrogen species generation, NF-κB activation and
cell death in primary human cardiomyocytes (Suppl.Figs.6-8).
The above mentioned beneficial effects of CBD could be explain in part by its potent
antioxidant properties, which was first suggested by the Nobel Prize winner Dr. Julius
Axelrod (31). In Axelrod's study CBD was more protective against glutamateinduced
neurotoxicity than any of the well-know antioxidants (e.g. ascorbate or α-tocopherol),
indicating additional cytoprotective effects of CBD beyond its potent antioxidant properties
(31). Indeed, our recent results suggest that CBD may exert potent effects on key pro-
inflammatory pathways such as NF-κB and on pro-survival signaling such as Akt in vivo,
which is most likely not related to its antioxidant effect. This is also supported by
observations that CBD decreases inflammation in models in which conventional
antioxidants are not very effective (e.g. in arthritis (20,32)), as well as by recent studies
demonstrating that CBD is a potent inhibitor of bacterial lipopolysaccharide-activated NF-
κB proinflammatory pathway in microglia cells(33). These results are also in support of the
emerging role of the inflammation in the development and progression of diabetic
cardiomyopathy (9,11,15,30).
Collectively, our results strongly suggest that CBD may have tremendous therapeutic
potential in the treatment of diabetic cardiovascular and other complications by attenuating
diabetes-induced oxidative/nitrosative stress, inflammation, cell death and fibrotic pathways.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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List of abbreviations
CBD cannabidiol
ICAM-1 Inter-Cellular Adhesion Molecule 1 or CD54
iNOS inducible nitric oxide synthase
3-NT 3-nitrotyrosine
MAPKs mitogen-activated protein kinases (e.g. p38 and JNK)
MMP 2 and 9 matrix metalloproteinases
NF-κB nuclear factor kappa B
NADPH oxidases nicotinamide adenine dinucleotide phosphate-oxidases
PARP poly(ADP-ribose) polymerase
TNF-α tumor necrosis factor alpha
TUNEL Terminal deoxynucleotidyl transferase dUTP nick end labeling
VCAM-1 vascular cell adhesion molecule-1 or CD106
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Fig.1. Cannabidiol attenuates diabetes-induced left ventricular dysfunction
A) Representative pressure–volume (P–V) loops at different preloads after inferior vena
cava occlusion, showing differences in the end-systolic and end-diastolic P–V relations
(ESPVR and EDPVR) in control and diabetic mice treated with vehicle or cannabidiol
(CBD). The shift of P-V loops right and changed slope of ESPVR and EDPVR in diabetic
mice indicates decreased systolic and diastolic functions, which were less pronounced in
diabetic mice treated with CBD (20 mg/kg/day) for 11 weeks. B) 12 weeks of diabetes was
associated with decrease in left ventricular systolic pressure (LVSP), maximum first
derivative of ventricular pressure with respect to time (+dP/dt), stroke work, ejection
fraction, cardiac output, and load-independent indexes of contractility (preload-recruitable
stroke work (PRSW), dP/dt–end-diastolic volume relation (dP/dt-EDV), and end-systolic
pressure–volume relation (Emax), respectively), and an increase in left ventricular end-
diastolic pressure (LVEDP) and prolongation of relaxation time constants (τ Weiss and
Glantz), which were largely attenuated by CBD treatment (20 mg/kg/day I.P.) for 11 weeks.
Results are mean±SEM of 8-11/group. *P<0.05 vs. vehicle control/CBD alone; #P<0.05 vs.
diabetes [D].
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Fig.2. CBD attenuates diabetes-induced myocardial oxidative stress
Oxidative stress in the myocardial tissues were determined by measuring (A) MDA, (B) 4-
HNE, (C) protein carbonyls content and (D) ROS levels by EPR as described in the
Methods section and the (E) NADPH oxidase subunits mRNA expression by real time RT-
PCR (F) endogenous antioxidants (GSH) content and (G) SOD activity. *P<0.05 vs. vehicle
control/CBD alone, #P<0.05 vs. diabetes [D], n=6-9/group.
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Fig.3. CBD attenuates diabetes-induced myocardial NF-κB activation
(A) Western blot analysis demonstrates IκB-α expression and its phosphorylation in the
cytosolic fraction and (B) the nuclear translocation of p65NF-κB in the nuclear fraction of
the heart tissue homogenates. (C) Shows the gel shift assay demonstrating NF-κB activation.
(D) Shows the mRNA expression of ICAM-1/VCAM-1 (E) TNF-α in the respective groups
as indicated (F) Shows the western blot analysis for the protein expression of ICAM-1/
VCAM-1 and (G) TNF-α protein in the myocardial tissues. *P<0.05 vs. vehicle control/
CBD alone; #P<0.05 vs. diabetes [D], n=6-9/group.
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Fig.4. CBD inhibits diabetes-induced myocardial, iNOS expression and 3-NT accumulation
(A) iNOS expression was determined by Western immunoblot in the heart tissues (B) 3-NT
levels in the heart samples were quantitatively determined by ELISA with indicated CBD
concentration (mg/kg body weight) respectively. (C) Representative gel indicating the
nitrated proteins analyzed by immunoprecipitation with 3-NT specific antibody (D) shows
the representative images for the histochemical staining for 3-NT levels in the formalin-
fixed myocardial tissues. (E) Depicts the immunofluorescence staining for 3-NT from frozen
sections as described in methods. *P<0.05 vs. vehicle control/CBD alone; #P<0.05 vs.
diabetes [D], n= 6-8/group.
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Fig.5. CBD mitigates diabetes-induced myocardial activation of MAPKs and augments Akt
activation
Western blot analysis shows the (A) p38MAPK (B) JNK (C) p38α/βMAPK (D)
MAPKAPK-2 and (E) Akt activation in the myocardial tissues. P<0.05 vs. vehicle control/
CBD alone; #P<0.05 vs. diabetes [D], n=6/group.
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Fig.6. CBD mitigates diabetes-induced myocardial apoptosis and cell death
(A) Western blot analysis for the caspase 3 and (B) caspase 3/7 activity (C) chromatin
fragmentation and (D) PARP activation and (E) quantitative TUNEL assay was performed
as described in Methods. *P<0.05 vs. vehicle control/CBD alone; #P<0.05 vs. diabetes [D],
n=6-9/group.
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Fig.7. CBD mitigates apoptosis in the diabetic myocardium
Shown are the representative TUNEL images in the diabetic myocardium and mice that
were treated with CBD for 11 weeks. For details see the supplemental methods.
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Fig. 8. CBD attenuates diabetes-induced cardiac fibrosis
(A) Shows the mRNA expression of the pro-fibrotic genes in the myocardial tissues.
*P<0.05 vs. vehicle control/CBD alone; #P<0.05 vs. diabetes [D], n=9/group. (B) Depicts
the Sirius red staining indicating collagen deposition and implying and the extent of cardiac
fibrosis. Images shown are representative from 4 independent experiments. *P<0.05 vs.
vehicle control/CBD alone; #P<0.05 vs. diabetes [D], n= 4-6/group.
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